← Leaderboards
Todd C Zion
Smartcells, Inc.
$12,707,266
Attributed
$12,707,266
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2005–20$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$12,707,266 · 9
By mechanism
R44$10,362,276 · 4
R43$2,344,990 · 5
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Blood Glucose”
- Rose A Gubitosi-Klug · Case Western Reserve University$56,959,998
- Jose A Luchsinger · Columbia University Health Sciences$47,880,063
- Walter N Kernan · Yale University$42,197,025
- Paul M. Ridker · Brigham And Women'S Hospital$34,275,148
- Katherine M Detre · University Of Pittsburgh At Pittsburgh$33,228,566
- Anastassios G Pittas · Tufts Medical Center$33,034,279
Research focus
Blood GlucoseInsulinSafetyBaseGlycemic ControlGlucose MonitorDietCellsDoseDosageSmall Business Innovation Research GrantDesignDiabetes MellitusDrug KineticsInjection Of Therapeutic AgentBinding (Molecular Function)DiabeticGrantAnimalsIn VivoAffinityIncidenceGlucoseIn Vitro
Grant awards (18)
IND-enabling assay validation and toxicology studies on AKS-107: a novel antigen-specific B cell therapeutic to prevent Type 1 Diabetes$923,642
R44 · FY2020 · DK · contact PI
IND-enabling assay validation and toxicology studies on AKS-107: a novel antigen-specific B cell therapeutic to prevent Type 1 Diabetes$978,643
R44 · FY2019 · DK · contact PI
Selective Depletion of Insulin-Specific B cells to Prevent Type 1 Diabetes$998,998
R44 · FY2018 · DK · contact PI
Selective Depletion of Insulin-Specific B cells to Prevent Type 1 Diabetes$998,123
R44 · FY2017 · DK · contact PI
Selective Removal of Insulin-Specific B-cells to Prevent Type I Diabetes in NOD Mice$249,821
R43 · FY2015 · DK · contact PI
Novel Compounds for Reducing Brain A-Beta Levels via Enhanced Systemic Clearance$249,926
R43 · FY2014 · AG · contact PI
SmartInsulin ADME and IND-enabling Preclinical Studies$337,365
R44 · FY2010 · DK · contact PI
SmartInsulin ADME and IND-enabling Preclinical Studies$1,578,278
R44 · FY2009 · DK · contact PI
SmartInsulin Stability, Process Development, Assay Validation and GMP Manufacturi$850,859
R44 · FY2009 · DK · contact PI
SmartInsulin Stability, Process Development, Assay Validation and GMP Manufacturi$1,546,698
R44 · FY2008 · DK · contact PI
SmartInsulin ADME and IND-enabling Preclinical Studies$1,116,164
R44 · FY2008 · DK · contact PI
Multimeric RNA Aptamers for Glucose-Responsive Insulin Formulations$335,073
R43 · FY2008 · DK · contact PI
Multimeric RNA Aptamers for Glucose-Responsive Insulin Formulations$394,363
R43 · FY2007 · DK · contact PI
SmartInsulin Stability, Process Development, Assay Validation and GMP Manufacturi$283,515
R44 · FY2007 · DK · contact PI
Safety Profile Optimization of Glucose-Regulated Insulin Formulations$749,991
R44 · FY2006 · DK · contact PI
Glucose-Responsive Self-Regulated Insulin Delivery$438,290
R43 · FY2005 · DK
RNA-Biopolymer Nanostructures for Smart Insulin Delivery$195,241
R43 · FY2005 · DK
Glucose-Responsive Self-Regulated Insulin Delivery$482,276
R43 · FY2004 · DK